S&P: Sanofi-Aventis unchanged

Standard & Poor's said its ratings on Sanofi-Aventis SA (AA-/stable/A-1+) are not affected by the likely loss of patent protection on its anti-thrombosis drug Plavix.

The agency said that this announcement followed the failed antitrust clearance of the group's earlier agreement with Canadian generic drugs manufacturer Apotex, which was essentially aimed at extending the period of Plavix's patent.

In addition, the U.S. Department of Justice is conducting a criminal investigation regarding the proposed settlement between the parties, S&P added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.